<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) causes <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> and is associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in immunocompromised populations </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="36044">Antiviral drugs</z:chebi> targeted against lytic <z:mp ids='MP_0001799'>viral</z:mp> replication have limited efficacy in these disease settings </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> of peripheral blood mononuclear cells induces growth proliferation and the EBV latency Epstein-Barr virus-encoded nuclear antigen (EBNA)2 transcriptional transactivator (TAT) is essential for this response </plain></SENT>
<SENT sid="3" pm="."><plain>EBNA2 targets the cellular DNA-binding protein CBF1 to mimic activated Notch signaling </plain></SENT>
<SENT sid="4" pm="."><plain>A 10-aa <z:chebi fb="7" ids="16670">peptide</z:chebi> from the CBF1 interaction domain of EBNA2 was synthesized as a fusion with the protein transduction domain of HIV-1 TAT </plain></SENT>
<SENT sid="5" pm="."><plain>The EBNA2-TAT <z:chebi fb="7" ids="16670">peptide</z:chebi> blocked EBNA2-CBF1 interaction in an in vitro GST affinity assay and labeling with <z:chebi fb="0" ids="31624">fluorescein</z:chebi> confirmed that the EBNA2-TAT <z:chebi fb="7" ids="16670">peptide</z:chebi> efficiently entered cultured B cells </plain></SENT>
<SENT sid="6" pm="."><plain>Neither EBNA2-TAT, nor a mutant <z:chebi fb="7" ids="16670">peptide</z:chebi> with a 2-aa substitution that was unable to block the EBNA2-CBF1 interaction, significantly affected the growth of non-EBNA2-expressing EBV(-) B cells or Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Akata cells </plain></SENT>
<SENT sid="7" pm="."><plain>However, treatment of an EBV-immortalized lymphoblastoid cell line with the EBNA2-TAT <z:chebi fb="7" ids="16670">peptide</z:chebi> stopped cell growth and reduced cell viability </plain></SENT>
<SENT sid="8" pm="."><plain>RT-PCR analyses of gene expression in the <z:chebi fb="7" ids="16670">peptide</z:chebi>-treated lymphoblastoid cell line cultures revealed that EBNA2-TAT treatment down-regulated the EBNA2-responsive <z:mp ids='MP_0001799'>viral</z:mp> LMP1 and LMP2 genes and cellular CD23, intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1, BATF, and Cdk1 genes while up-regulating expression of the cyclin-dependent kinase inhibitor p21 </plain></SENT>
<SENT sid="9" pm="."><plain>EBV-induced outgrowth of B cells from cultured peripheral blood mononuclear cells was also blocked in a dose-responsive manner by the EBNA2-TAT <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>This study suggests that cell-permeable EBNA2 <z:chebi fb="7" ids="16670">peptides</z:chebi> may have potential as novel anti-EBV therapeutics </plain></SENT>
</text></document>